SEC Form 4 · accession 0001209191-18-021358
Clearside Biomedical, Inc. · CLSD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald D. Cagle
Director
Period of report
Mar 22, 2018
Accepted (ET)
Mar 23, 2018 · 9:17 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001539029
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 22, 2018 | P | 7,500 | $11.89 | A | 23,441 | D | |
| Common StockF2 | holding | — | — | — | 14,064 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $11.83 to $11.95, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2Cagle Business Interests, Ltd. is the record holder of these securities. The reporting person is the general partner of Cagle Business Interests, Ltd. and may be deemed to share voting and dispositive power over these securities. The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.